1832 Asset Management L.P. Supernus Pharmaceuticals, Inc. Transaction History

1832 Asset Management L.P.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2018 Nov 14, 2018	SELL	$42.7 - $56.55 $35.3 Million - $46.7 Million	-825,900 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$44.1 - $59.85 $36.4 Million - $49.4 Million	825,900 New	825,900 $48.3 Million

290

60.7M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.05B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of 1832 Asset Management L.P., based on Form 13F filings with the SEC.

Stay updated on 1832 Asset Management L.P. with notifications on news.